ArticleHematological oncology2026
Real-World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis.
Article in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard-of-care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality-of-life. Venetoclax is metabolized mainly by cytochrome P450 3A4 enzymes and serves as a P-glycoprotein substrate, which make it largely affected by interactions with drugs. Dose reductions are needed to allow mold active antifungal prophylaxis, but there is no consensus on the exact venetoclax target dose concomitantly with posaconazole. We report on efficacy and safety of venetoclax combinations in 38 first-line (FL) and 51 relapsed-refractory (R/R) AML patients. Although complete remission (CR) rate was lower in R/R than in FL (49% vs. 68%; p = 0.08), achievement of this status was associated with comparable median overall survival (OS) in R/R and FL (13.67 vs. 13.72 months). Eighteen (20%) patients underwent allogenic hematopoietic stem cell transplantation (HSCT) with a 2-year OS probability of 66.7%. Although antifungal prophylaxis was associated with a lower rate of grade 3-4 fungal infections (6% vs. 24%, p 0.044), patients treated with venetoclax daily dose of 50 mg with posaconazole had significantly shorter mOS in multivariate analysis (16.5 vs. 4.5 months; p 0.011). We conclude that AML patients in remission with venetoclax combinations may still be consolidated, and potentially cured, by HSCT, even after failure of intensive chemotherapy. Posaconazole prophylaxis effectively reduces risk of severe fungal infections, but a concomitant venetoclax dose of 50 mg may be sub-optimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.